The Fraudulent World of Hurricane Restoration

Posted by & filed under Accounting Principles, All Articles, Fraud Accounting.

Home Solutions of America, Inc., a hurricane restoration company, is charged by the SEC with recording millions of dollars in bogus revenues and issuing misinformation to fraudulently inflate its stock price. The scheme was compounded by transactions that occurred between Home Solutions and Fireline Restoration Inc., its largest subsidiary. All of this alleged activity happened… Read more »

Is the SEC Going to Get Tough On Compliance with Executive Pay Disclosures?

Posted by & filed under All Articles, Financial Reporting and Analysis, Financial Statement Analysis.

The SEC revised its disclosure guidelines for executive pay in late 2006. Since that time the regulator has been sending out letters to violator companies with insufficient disclosures, but has seen little compliance. Now the commission indicates that reviews will be tighter and there’s no room for a “Mister Nice Guy” approach. In fact, its… Read more »

Evidence that Internal Control Reviews Reduce Restatements

Posted by & filed under All Articles, Auditing.

According to a new study from the research firm, Audit Analytics, smaller companies that have not had auditors review their internal-control reports are more likely to have restatements than larger companies, despite their claims of effective controls. This is bad news for those small publicly traded companies who have argued that they should be exempt… Read more »

Recessionary Cost-Cutting Revisited

Posted by & filed under All Articles, Cost Accounting, Managerial Accounting.

In an effort to keep their heads above water in recessionary times, many companies ignored their traditional strategic plans. They grabbed at any transactions that were above variable costs in efforts to cover fixed costs. Moving away from value-based pricing, they relied on cost-plus pricing. Unfortunately, as this article mentions, cost-cutting can only go so… Read more »

Times are Tough for Everyone: Including the PCAOB!

Posted by & filed under All Articles, Auditing.

Just a week before the Supreme Court hears oral arguments about constitutionality of the Public Company Accounting Oversight Board (PCAOB) and why it should be dissolved, the members of the Board asked for a 16% in the overseer’s 2010 budget. This amounts to an additional $25.7 million to hire 60 more employees, for international inspections,… Read more »

What Will the Future Bring for Lease Accounting?

Posted by & filed under All Articles.

CEOs and CFOs are cautiously eyeing the limitations that convergence of FASB and IFRS standards may bring to lease accounting. Predictions are that a new global lease standard, anticipated in 2011, will require many traditionally classified operating leases into the capital lease status. QUESTIONS: What are the current FASB criteria for classifying leases as either… Read more »

What are Non-GAAP Financial Measures?

Posted by & filed under All Articles.

Amgen is a biotechnology firm that develops and manufactures human therapeutics that fight cancer, kidney disease, rheumatoid arthritis and other serious illnesses. As part of its 2008 financial report, the Company issued non-GAAP financial measures to facilitate additional analysis by investors. QUESTIONS: In one paragraph, briefly describe non-GAAP financial measures and how they differ from… Read more »

Boosting Liquidity

Posted by & filed under All Articles.

On Tuesday, November 24, 2009, U.S. Airways announced several ways that it will boost its current and future liquidity. Since beginning its innovative slot transaction with Delta Air Lines, the company has been trying to realign a number of financial areas to focus on their most profitable flying operations. QUESTIONS: What is liquidity and explain… Read more »

Raising funds with Stock Warrants

Posted by & filed under All Articles, Financial Reporting and Analysis, Financial Statement Analysis, Intermediate Accounting.

The biotechnology firm, Dendreon Corporation, is a company which is developing the prostate cancer drug Provenge. On Friday, November 20, the U.S. Food and Drug Administration (FDA) accepted its application to market the vaccine to treat men with advanced prostrate cancer. If the FDA approves it, the drug would be the first in a new… Read more »